NXNL1 and retinitis pigmentosa: Recently, a first-in human Phase1/2 clinical trial evaluating a gene-independent, cone-preserving therapy for retinitis pigmentosa using SPVN06, i.e., a human-engineered AAV that delivers RdCVF gene in retinal cells, has commenced at a low dose and is ongoing at a medium dose (NCT05748873).